NRSN (NeuroSense Therapeutics) Buyback Yield %: -16.53 (As of Jun. 27, 2026)


NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Buyback Yield %?

NeuroSense Therapeutics NRSN -0.21% 31 Buyback Yield % is -16.53 as of Jun. 27, 2026. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 743 Biotechnology companies, NeuroSense Therapeutics ranks worse than 62.31% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

NeuroSense Therapeutics's current buyback yield was -16.53%.

NeuroSense Therapeutics Buyback Yield % Related Terms

NeuroSense Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Buyback Yield % Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -36.64 0.00 -35.90 -40.55 -18.10

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.90 -21.73 -40.55 -17.77 -18.10

NRSN vs SNTI, LSTA, DYAI: Buyback Yield % Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Buyback Yield % falls into.


NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

NeuroSense Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 4.531) / 25.036333
=-18.10%

NeuroSense Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 4.531) / 25.036333
=-18.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -16.53 mean?
NeuroSense Therapeutics (NRSN) has a Buyback Yield % of -16.53 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NeuroSense Therapeutics and its competitors. According to the industry distribution chart, NeuroSense Therapeutics ranks #463 out of 743 companies in the Biotechnology industry, placing it in the top 62.3%.
Is NeuroSense Therapeutics' Buyback Yield % too high?
NeuroSense Therapeutics' current Buyback Yield % is -16.53. Based on the distribution chart, NeuroSense Therapeutics ranks #463 out of 743 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Buyback Yield % compare to SNTI and LSTA?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #463 out of 743 companies for Buyback Yield %. This places NeuroSense Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Buyback Yield % is -16.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Buyback Yield % of -16.53. The current Buyback Yield % is -16.53. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Buyback Yield % is -16.53 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price